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The central nervous system is involved early in the course
of HIV and without treatment frequently is seriously dam-
aged resulting in a serious HIV-associated dementia. This
is believed to be due to direct toxicity of viral proteins and
indirect damage from inflammatory reaction in the brain
over long periods of time. The advent of highly active
antiretroviral therapy has almost eliminated severe
dementia in the treated HIV population. However, careful
examination of patients in our clinics continues to show a
majority of chronically infected, treated patients suffer
measurable neurocognitive impairment. While this con-
dition is mild in most cases, it may impact long-term
quality of life, and might suggest early manifestation of
accelerated cognitive decline with aging. Preliminary evi-
dence links low level viral replication determined in the
CSF of treated patients with inferior neurocognitive out-
comes. There is also evidence of residual neuro-inflamma-
tory activity in the CNS of chronically treated patients, a
finding consistent with the hypothesis that ongoing infec-
tion may still drive pathology in the brain through smoul-
dering inflammatory responses. One available means of
improving outcome could be to target HIV therapies for
the brain. When HIV therapies are categorized according
to their effectiveness in the brain or CSF, recent evidence
supports better cognitive outcomes with more highly
effective drug regimens. Ongoing research is critical to
determine if outcomes of HIV therapy can be improved by
selection of drugs with better CNS penetrating properties.
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